Botulinum toxin consent form template

Key Takeaways

A botulinum toxin consent form documents informed patient agreement before treatment, protecting both practices and practitioners from liability disputes.

The form must disclose the FDA black box warning about distant toxin spread, product selection, off-label use, and common side effects including bruising, asymmetry, and temporary weakness.

UK practices must retain signed botulinum toxin consent forms for a minimum of 8 years per NHS guidance; GDPR requires explicit consent for digital storage and processing.

Pabau’s digital forms feature captures patient signatures electronically, automates consent workflows, and maintains tamper-proof audit trails for regulatory compliance.

A comprehensive botulinum toxin consent form protects your practice and ensures patients fully understand the risks, benefits, and expectations of treatment before receiving injections. Whether you’re a solo aesthetician, multi-location med spa, or clinical dermatologist, this template provides the legal safeguards and regulatory compliance your practice needs.

What is a botulinum toxin consent form?

A botulinum toxin consent form is a legal document that confirms a patient has received informed consent before receiving botulinum toxin injections (such as Botox, Dysport, Xeomin, Jeuveau, or Bocouture — noting that Bocouture is a UK/EU product not FDA-approved in the US).

The form documents the patient’s understanding of the procedure, acknowledges receipt of risk information, and confirms voluntary agreement to treatment.

In the UK, informed consent is a legal and professional requirement under the Montgomery v Lanarkshire ruling (2015), which established that patients must receive information about material risks and alternatives. Practitioners must also comply with CQC registration standards, Save Face accreditation, and GMC/NMC professional guidance.

In the US, HIPAA-compliant consent documentation is essential; in the UAE, the Dubai Health Authority (DHA) and NABIDH platform require traceable consent records.

Botulinum toxin carries an FDA black box warning about the potential for distant spread of toxin effect, meaning the consent form must explicitly disclose this risk alongside common side effects such as bruising, swelling, asymmetry, and temporary facial weakness.

How to use your botulinum toxin consent form

Follow these five operational steps to integrate the botulinum toxin consent form into your practice workflow:

1. Patient medical history screening. Ask patients to complete the form’s medical history section at the initial consultation, before the treatment day. This section captures relevant conditions-pregnancy status, breastfeeding, neuromuscular disorders (myasthenia gravis, Lambert-Eaton syndrome), anticoagulant use, recent Botox/Dysport treatments within the past 3 months, and allergies to botulinum toxin or albumin. Document any contraindications that would prevent safe treatment.
2. Procedure explanation and alternatives. Walk the patient through the intended treatment areas (glabellar lines, forehead, crow’s feet, masseter reduction, gummy smile, or off-label uses) as part of a thorough botox consultation. Explain the mechanism (temporary muscle relaxation lasting 3-4 months), realistic results, and downtime expectations. Offer alternatives: dermal fillers, non-invasive rejuvenation (laser, microneedling), or no treatment. The form must acknowledge these alternatives are available.
3. Risk disclosure and FDA black box acknowledgement. Review the form’s risks and side effects section aloud: bruising and swelling (48-72 hours), asymmetry (requiring touch-up at 2 weeks), ptosis (temporary eyelid droop if injected above the brow), diplopia (rare double vision), dysphagia (rare difficulty swallowing if injected into neck muscles), and distant toxin spread (FDA black box warning). Confirm the patient understands each risk.
4. Signature and consent capture. Obtain the patient’s dated signature on the form, confirming they have read, understood, and voluntarily consented to treatment. If using digital consent software such as Pabau’s digital forms, capture the electronic signature and timestamp it. Ensure the patient receives a copy and retain the original (or digital copy) securely.
5. Post-treatment acknowledgement and storage. Document the injection sites, product used (brand and lot number), units administered, and batch details in the patient’s clinical record. Store the signed consent form in a GDPR-compliant system (UK: minimum 8 years retention for adults) with access controls, encryption, and audit trails. For US practices, maintain HIPAA-compliant storage with business associate agreements (BAAs) if using cloud storage.

Using compliance management software ensures consent forms are stored securely, automatically retained for the required period, and retrievable during audits or complaints investigations.

Who is a botulinum toxin consent form helpful for?

This template is essential for aesthetic practitioners across multiple specialties and practice models:

• Aesthetic clinics and med spas offering preventive and therapeutic botulinum toxin treatments to elective cosmetic clients, often alongside a broader spa intake form.
• Dermatology practices using dermatology practice management software to track botulinum toxin for dynamic wrinkles, hyperhidrosis, and other dermatological indications.
• Plastic surgery practices performing botulinum toxin as part of comprehensive facial rejuvenation.
• Independent practitioners (nurse practitioners, physician assistants, registered nurses with prescriber qualification — see can nurses administer Botox injections) delivering botulinum toxin in private practice settings.
• Multi-location practice groups requiring standardized consent documentation across all sites.
• UK practitioners needing CQC-compliant and Save Face-aligned consent processes.
• US medical spas requiring HIPAA-compliant consent records and state-specific scope-of-practice documentation.

Benefits of using a botulinum toxin consent form

A well-constructed botulinum toxin consent form delivers multiple operational and legal benefits:

• Legal protection. Documented informed consent protects practices and practitioners against claims of negligence or inadequate disclosure. Consent does not waive patient rights to seek damages, but it demonstrates the practitioner fulfilled the duty of care.
• Regulatory compliance. Meets requirements from CQC (England), HIS (Scotland), Save Face, JCCP, MHRA, and GMC/NMC professional guidance in the UK. In the US, supports HIPAA compliance; in the UAE, satisfies DHA and NABIDH requirements.
• Clinical workflow efficiency. A standardized form ensures all essential information is captured consistently, reducing omissions and follow-up clarifications.
• FDA black box acknowledgement. Explicit documentation that the patient understands the black box warning about distant toxin spread satisfies FDA post-market surveillance expectations and reduces regulatory exposure.
• Audit and complaints management. Signed consent forms create a complete record for CQC inspections, patient complaints, and medico-legal investigations. Digital storage with audit trails (timestamps, IP addresses, signature verification) strengthens evidence of compliance.
• Professional credibility. Comprehensive, professionally worded consent forms signal a practice committed to patient safety and regulatory standards, building trust with referring physicians and patients.

Regulatory requirements and off-label disclosure

Botulinum toxin products carry specific regulatory approvals and off-label use restrictions:

• FDA approved indications (US): Approved cosmetic indications vary by product. Botox Cosmetic (onabotulinumtoxinA) is FDA-approved for glabellar lines, crow’s feet, and forehead lines. Dysport, Xeomin, and Jeuveau are approved for glabellar lines only (cosmetic). Other uses (forehead lines with non-Botox products, masseter reduction, gummy smile, hyperhidrosis, bruxism) are off-label for those products and must be disclosed in the consent form as unapproved by the FDA.
• MHRA approved indications (UK): Similar approved indications; off-label uses require explicit patient consent and should be documented as such. Botulinum toxin is a prescription-only medicine (POM) in the UK; only doctors, dentists, and specialist nurses can prescribe.
• Product-specific contraindications: Absolute contraindications include pregnancy, breastfeeding, myasthenia gravis, Lambert-Eaton syndrome, and allergy to botulinum toxin. Relative contraindications include anticoagulant therapy, facial weakness, or recent Botox treatment within 3 months.
• Data retention rules (UK): NHS guidance and the BMA recommend retaining consent forms and clinical records for a minimum of 8 years for adult patients. GDPR requires explicit consent for any digital processing or transfer of personal data; consent withdrawal rights must be documented.

When using medical spa software to manage consent forms, ensure the platform logs consent withdrawal, automatically deletes records after the retention period expires, and provides GDPR-compliant data handling.

Digital vs. paper consent: which is right for your practice?

Paper consent forms are legally valid but carry storage, retrieval, and compliance risks. Digital consent platforms offer significant advantages:

• Paper forms: Low upfront cost, familiar to patients, but require physical storage space, manual retrieval during audits, vulnerability to damage or loss, and manual compliance tracking.
• Digital forms with e-signatures: Captured via practice management software, timestamped, encrypted, and searchable. Audit trails show who viewed and signed the form and when. Automatic retention schedules ensure compliance with UK (8-year) and US (typically 6-10 year) retention rules. Integration with patient portals allows pre-appointment completion, reducing practice bottlenecks.
• Hybrid approach: Many practices capture digital consent pre-appointment, print a copy for patient review during the consultation, and retain both digital and printed versions. This balances convenience with a tangible record the patient receives.

For multi-location practices, practice management software with centralized form management standardizes consent across all sites and simplifies compliance audits.

See How Pabau Simplifies Consent Management

Pabau's digital forms capture patient consent electronically, store records securely with compliance audit trails, and integrate with your patient management workflow.

Book a demo

Key clauses to include in your botulinum toxin consent form

Every botulinum toxin consent form should include these essential clauses:

• Patient identification and procedure description. Name, date of birth, contact details, and a clear description of which areas will be injected (glabellar lines, forehead, crow’s feet, etc.), which product will be used (Botox, Dysport, Xeomin, Bocouture), and the approximate units and cost.
• Medical history screening. Pregnancy/breastfeeding status, neuromuscular disorders, anticoagulant use, recent Botox/filler treatments, and allergies. A checkbox confirming the patient is not pregnant, nursing, or immunocompromised.
• FDA black box warning. A specific statement that botulinum toxin carries an FDA black box warning about distant spread of toxin effect beyond the injection site, potentially causing weakness, swallowing difficulty, or breathing problems (rare but serious). This must be acknowledged by initials.
• Off-label disclosure. For non-FDA-approved indications, a statement that the treatment is off-label and the patient understands this is an unapproved use.
• Risks and side effects. Common side effects (bruising, swelling, asymmetry, temporary weakness), less common risks (ptosis, diplopia, dysphagia), and rare but serious risks (systemic toxin spread). Patient initials required.
• Realistic expectations. Results typically begin to appear within 24–72 hours, with initial effects visible within a few days, peaking at 2 weeks and lasting 3–4 months. Touch-up appointments may be needed to correct asymmetry. No guarantee of satisfaction or specific outcomes.
• Alternatives to treatment. List alternative treatments (dermal fillers, laser, microneedling, non-invasive options, no treatment) and confirm the patient chose botulinum toxin after discussion.
• Voluntary consent. A statement that the treatment is elective and the patient is not under pressure. The patient has had an opportunity to ask questions and received satisfactory answers.
• Right to withdraw. Acknowledgement that the patient may withdraw consent at any time before treatment (depending on jurisdiction, withdrawal after signing may carry cancellation fees).
• Liability release clause. A carefully worded statement that the patient releases the practice from liability for foreseeable, disclosed risks but does NOT waive the patient’s right to seek damages for negligence or breach of duty (as confirmed by UK case law).
• Photography and before/after consent. Separate checkboxes for consent to clinical photography, use in before/after marketing, and use of images in training materials.
• Data protection and storage. Confirmation that the patient consents to digital storage and processing of their consent form in accordance with GDPR (UK), HIPAA (US), or applicable privacy law (UAE). Patient right to access, correct, or delete data.
• Signature and dating. Patient signature (or electronic signature), printed name, date, and practitioner signature confirming they delivered informed consent discussion.

Common mistakes to avoid

Practitioners often make these consent form mistakes, undermining compliance and increasing liability exposure:

• Generic templates without customization. Using a template designed for a different jurisdiction or procedure type without adapting it to your specific practice, patient population, and product. Customize for your location (UK GDPR/CQC, US state-specific, UAE DHA) and injectable products.
• Insufficient risk disclosure. Listing only common side effects while omitting rare but serious risks (distant toxin spread, severe asymmetry, systemic reactions). Incomplete risk disclosure undermines the legal purpose of informed consent.
• Missing FDA black box warning. Failing to explicitly disclose and obtain patient initials on the black box warning about distant toxin spread. The FDA expects this documented in post-market surveillance.
• No off-label disclosure. When using botulinum toxin for non-FDA-approved indications (hyperhidrosis, masseter reduction, bruxism), failing to disclose off-label status. The consent form must state this is an unapproved use.
• Overly broad liability release language. Attempting to release liability for practitioner negligence. Consent does not waive patient rights; it documents informed agreement to disclosed, foreseeable risks. Courts may void over-reaching liability clauses.
• No documentation of alternatives offered. Listing alternatives without documenting that they were discussed and the patient chose botulinum toxin knowingly. This is a cornerstone of Montgomery-compliant informed consent.
• Inadequate digital storage and retention tracking. Storing digital consent forms without encryption, backup, or automated deletion schedules, creating GDPR/HIPAA violations and retrieval chaos during audits.
• Unsigned or incomplete consent. Accepting unsigned forms or forms with blank fields. Every required field and signature must be completed before treatment proceeds.

Storing and retrieving signed consent forms

Secure, compliant storage is as critical as the consent form itself:

• UK practices (CQC, GDPR): Retain for 8 years minimum (adults), encrypted and access-controlled. Store with patient clinical records in a system with role-based permissions, audit logs, and automatic backup. GDPR requires documented consent for digital processing and clear data retention policies.
• US practices (HIPAA): Retain for 6-10 years depending on state requirements. Store in a HIPAA-compliant system (cloud or on-premise) with business associate agreements (BAAs), encryption, and access logs. Train staff on HIPAA privacy and security rules.
• UAE practices (DHA/NABIDH): Comply with UAE Federal Medical Liability Law and NABIDH platform requirements. Retain for 5-7 years minimum (subject to local guidance), store encrypted with audit trails, and ensure data residency compliance (some data may need to remain in UAE servers).

Going paperless with a practice management system reduces physical storage costs and accelerates retrieval during compliance audits or patient complaints investigations.

Conclusion

A comprehensive botulinum toxin consent form is the foundation of safe, ethically sound aesthetic practice. It documents informed patient agreement, discloses material risks (including the FDA black box warning), acknowledges alternatives, and protects your practice against liability disputes.

By using this template, customizing it for your jurisdiction, and storing signed forms securely with digital compliance tools, you demonstrate a practice committed to patient safety, regulatory compliance, and professional excellence. Book a demo with Pabau to see how digital forms and compliance management streamline consent capture and audit readiness across your practice.

Continue your research

Need guidance on UK professional consent standards? How to Prepare for a Cosmetic Client Consultation walks through the pre-treatment planning and informed consent discussion workflow.

Interested in template-based patient intake? Dermal Filler Consent Form Template provides a companion template for filler treatments often combined with botulinum toxin.

Want to automate consent workflows? Medical Spa Consultation Form Template covers the broader intake and consultation capture process.

Frequently asked questions